Literature DB >> 12095153

Pure red cell aplasia developing into myeloproliferation with myelodysplasia and subsequent leukemia after cyclosporin A therapy.

Takahiro Yamauchi1, Haruhisa Shirasaki, Atsushi Kuwata, Taro Yamashita, Shin Imamura, Hiroshi Tsutani, Takanori Ueda.   

Abstract

We describe a very rare case of a patient who presented with red cell aplasia that later developed into myeloproliferation with myelodysplasia and eventually leukemia. A 63-year-old man presented with anemia and reticulocytopenia in May 1997. A bone marrow examination revealed erythroid aplasia with normal production of myeloid cells and megakaryocytes with a normal karyotype. After the diagnosis of pure red cell aplasia was made, the patient was treated with prednisolone and then with cyclosporin A (CyA). Two weeks after the initiation of CyA treatment, the peripheral reticulocyte count began to increase with a regrowth of erythroid cells in the bone marrow. Meanwhile, the peripheral white blood cell and platelet counts also increased to more than 10,000/microL and 1,000,000/microL, respectively. Examination of a bone marrow aspirate in December 1997 revealed myelodysplastic changes with trisomy 8. Despite the discontinuation of CyA and the administration of 1-beta-D-arabinofuranosylcytosine stearyl monophosphate, leukemia developed in August 1998. In September 1998, the patient died of sepsis during a neutropenic period that followed remission-induction therapy. In the mechanism of pathogenesis, CyA may induce upon pure red cell aplasia a secondary myeloproliferative disorder with myelodysplasia and leukemia. An alternative possibility is that CyA reduces autoimmune-mediated suppression of the underlying stem cell disorder and that the result of this reduction is the manifestation of myeloproliferation and leukemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12095153     DOI: 10.1007/bf02982116

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  26 in total

Review 1.  The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated.

Authors:  N S Young
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

2.  Successful treatment of acquired myelofibrosis with pure red cell aplasia by cyclosporine.

Authors:  Y Nemoto; H Tsutani; S Imamura; T Ishizaka; Y Urasaki; T Fukushima; T Ueda
Journal:  Br J Haematol       Date:  1999-02       Impact factor: 6.998

3.  Autoimmune myelodysplasias.

Authors:  P A Miescher; H Favre; P Beris
Journal:  Semin Hematol       Date:  1991-10       Impact factor: 3.851

4.  Antilymphocyte globulin for myelodysplastic syndrome.

Authors:  A Tichelli; A Gratwohl; A Wuersch; C Nissen; B Speck
Journal:  Br J Haematol       Date:  1988-01       Impact factor: 6.998

5.  Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies.

Authors:  L Catalano; C Selleri; C Califano; L Luciano; M Volpicelli; S Rocco; G Varriale; P Ricci; B Rotoli
Journal:  Haematologica       Date:  2000-02       Impact factor: 9.941

6.  Pure red cell aplasia associated with chronic myelomonocytic leukaemia.

Authors:  A López-Guillermo; F Cervantes; E Sacanella; L Florensa; C Rozman
Journal:  Clin Lab Haematol       Date:  1989

7.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.

Authors:  A Jonásova; R Neuwirtová; J Cermák; V Vozobulová; K Mociková; M Sisková; I Hochová
Journal:  Br J Haematol       Date:  1998-02       Impact factor: 6.998

Review 8.  Myelodysplastic syndrome with erythroid hypoplasia/aplasia: a case report and review of the literature.

Authors:  J García-Suárez; T Pascual; M A Muñoz; B Herrero; A Pardo
Journal:  Am J Hematol       Date:  1998-08       Impact factor: 10.047

9.  Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy.

Authors:  H Enright; H S Jacob; G Vercellotti; R Howe; M Belzer; W Miller
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

Review 10.  Idiopathic myelofibrosis: historical review, diagnosis and management.

Authors:  I M Weinstein
Journal:  Blood Rev       Date:  1991-06       Impact factor: 8.250

View more
  2 in total

1.  Self-limiting pregnancy-associated pure red cell aplasia developing in two consecutive pregnancies: case report and literature review.

Authors:  Yoko Edahiro; Hajime Yasuda; Kiyoshi Ando; Norio Komatsu
Journal:  Int J Hematol       Date:  2019-12-09       Impact factor: 2.490

2.  Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit?

Authors:  Saloni Tanna; Celalettin Ustun
Journal:  Int J Hematol       Date:  2009-09-18       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.